PFNX News and Press, Pfenex Inc. From 02/28/19

Pfenex ( PFNX +2.6% ) expands its agreement with Alvogen Ltd. to develop and commercialize PF708, a biosimilar to Eli Lilly's ( LLY +0.8% ) osteoporosis med FORTEO (teriparatide), to the EU, certain countries in Middle East and North Africa (MENA) and rest-of-world (ROW) territori...

SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) and Alvogen Ltd. today announced entering into agreements expanding their collaboration to develop and commercialize Pfenex’s lead product candidate, PF708, a proprietary teriparatide therapeutic equivalen...

SAN DIEGO, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology® to improve protein therapies for unmet patient needs, announced today that Ee...

SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs, today announced that it will re...

The FDA has accepted for review Pfenex's (NYSEMKT: PFNX ) NDA for PF708, a Forteo therapeutic equivalent in the treatment of osteoporosis. More news on: Pfenex, Healthcare stocks news, Read more ...

SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the 505(b)(2) New Drug Application (NDA) for the Company’s lead product candidate, PF708, a Forteo® therapeutic...

The Portfolio Barometer Using an inductive portfolio model approach that goes where the types of returns in the market are strongest, I monitor different fundamental, value, momentum, forensic, and anomaly portfolios from financial research to create a portfolio barometer. This article conti...